晚期非小细胞肺癌免疫治疗超进展的研究进展

Advances in Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immunotherapy

超进展(hyperprogressive disease,HPD)是一种由免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗导致的进展模式。它表现为肿瘤爆发式生长和极差的患者预后。目前各研究中HPD的定义不尽相同。虽然已经发现HPD与多种临床病理特点和基因类型有关,但目前仍没有可以准确预测它的肿瘤标志物,而且潜在的机制也尚在研究中。本文着眼于晚期非小细胞肺癌,对HPD的研究现状进行综述,以期给采用ICIs药物治疗患者的临床医生提供有益的参考。

Hyperprogressive disease(HPD)is a novel pattern of progression caused by immune checkpoint inhibitors(ICIs).It is characterized by a dramatic tumor surge and is associated with poor clinical outcomes.Up to now,the definition of HPD is still controversial across various studies.Although it has been indicated that HPD has related to multiple clinicopathological features and genetic alterations,it is lack of biomarker to predict its occurrence,and the potential mechanism remains unknown.This review is to summarize current data on HPD specialized in the field of non-small cell lung cancer.And we expect to provide helpful clinical strategies for oncologists using ICIs.